$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913034655 Filed on April 30, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$0.00	$0.00	$147.0K
YoY Change		-100.0%	-86.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.200M	$3.900M	$2.600M
YoY Change	44.83%	50.0%	-3.7%
% of Gross Profit
Research & Development	$17.88M	$16.38M	$12.07M
YoY Change	58.87%	35.75%	27.87%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K	$230.0K
YoY Change	-66.67%	-56.52%	-47.61%
% of Gross Profit
Operating Expenses	$22.06M	$20.26M	$14.71M
YoY Change	56.1%	37.7%	21.5%
Operating Profit	-$22.06M	-$20.26M	-$14.57M
YoY Change	56.1%	39.09%	32.82%
Interest Expense	-$724.0K	-$470.0K	-$486.0K
YoY Change	48.97%	-3.29%	11.72%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$22.80M	-$20.70M	-$15.10M
YoY Change	56.16%	37.09%	32.46%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.80M	-$20.70M	-$15.10M
YoY Change	56.16%	37.09%	32.46%
Net Earnings / Revenue			-10272.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$11.40M	-$10.35M	-$9.438M
COMMON SHARES
Basic Shares Outstanding	69.13M shares	69.05M shares	56.37M shares
Diluted Shares Outstanding			56.37M shares

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.20M	$90.40M	$57.40M
YoY Change	57.05%	57.49%	42.79%
Cash & Equivalents	$33.78M	$34.96M	$34.55M
Short-Term Investments	$36.40M	$55.40M	$22.80M
Other Short-Term Assets	$1.600M	$1.500M	$600.0K
YoY Change	100.0%	150.0%	20.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$71.84M	$91.87M	$58.00M
YoY Change	57.89%	58.4%	42.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.620M	$1.350M	$1.324M
YoY Change	38.94%	1.96%	-26.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$464.0K	$481.0K	$519.0K
YoY Change	-7.2%	-7.32%	29.75%
Total Long-Term Assets	$2.084M	$1.831M	$1.843M
YoY Change	22.59%	-0.65%	-12.24%
TOTAL ASSETS
Total Short-Term Assets	$71.84M	$91.87M	$58.00M
Total Long-Term Assets	$2.084M	$1.831M	$1.843M
Total Assets	$73.92M	$93.70M	$59.84M
YoY Change	56.62%	56.58%	39.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.222M	$5.719M	$3.040M
YoY Change	49.2%	88.13%	78.82%
Accrued Expenses	$9.500M	$7.700M	$6.500M
YoY Change	37.68%	18.46%	20.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.300M	$3.100M	$6.100M
YoY Change	-32.91%	-49.18%	8.93%
Total Short-Term Liabilities	$20.07M	$16.55M	$15.64M
YoY Change	9.95%	5.8%	-9.57%
LONG-TERM LIABILITIES
Long-Term Debt	$18.40M	$20.50M	$10.40M
YoY Change	119.05%	97.12%	-9.57%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$18.42M	$20.55M	$10.43M
YoY Change	119.25%	97.04%	-16.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.07M	$16.55M	$15.64M
Total Long-Term Liabilities	$18.42M	$20.55M	$10.43M
Total Liabilities	$38.49M	$37.10M	$26.07M
YoY Change	44.15%	42.29%	-12.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$504.7M		-$413.5M
YoY Change
Common Stock	$540.2M	$538.5M	$447.2M
YoY Change		20.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.44M	$56.60M	$33.77M
YoY Change
Total Liabilities & Shareholders Equity	$73.92M	$93.70M	$59.84M
YoY Change	56.74%	56.58%	39.49%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$22.80M	-$20.70M	-$15.10M
YoY Change	56.16%	37.09%	32.46%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$230.0K
YoY Change	-66.67%	-56.52%	-47.61%
Cash From Operating Activities	-$19.92M	-$22.21M	-$15.25M
YoY Change	52.06%	45.64%	18.77%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	$276.0K	$147.0K
YoY Change	550.0%	87.76%	1370.0%
Acquisitions
YoY Change
Other Investing Activities	$19.01M	-$36.34M	-$13.17M
YoY Change	405.59%	175.93%	312.85%
Cash From Investing Activities	$18.62M	-$36.62M	-$13.32M
YoY Change	403.24%	174.92%	316.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.045M	$28.20M
YoY Change		-96.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	120.0K	12.28M	33.05M
YoY Change	-72.73%	-62.84%	1473.81%
NET CHANGE
Cash From Operating Activities	-19.92M	-22.21M	-15.25M
Cash From Investing Activities	18.62M	-36.62M	-13.32M
Cash From Financing Activities	120.0K	12.28M	33.05M
Net Change In Cash	-1.180M	-46.55M	4.480M
YoY Change	-86.83%	-1139.06%	-132.14%
FREE CASH FLOW
Cash From Operating Activities	-$19.92M	-$22.21M	-$15.25M
Capital Expenditures	-$390.0K	$276.0K	$147.0K
Free Cash Flow	-$19.53M	-$22.49M	-$15.40M
YoY Change	49.77%	46.04%	19.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	538538000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536277000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-461220000	USD
CY2013Q1	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	18000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	3000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	18000	USD
CY2013Q1	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	11000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	230000	USD
CY2011Q1	snta	Amount Of Grant Awarded AmountOfGrantAwarded	1000000	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21270000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20096000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1174000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21546000	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20196000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1350000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2013Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1072000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	999000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	609000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	856000	USD
CY2013Q1	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	2839000	USD
CY2012Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	5127000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1216000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	827000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M14D
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18968000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1158000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3272000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	56604000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	75066000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	618000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9363000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9114000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4531000	USD
CY2013Q1	us-gaap	Secured Debt SecuredDebt	23626000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34962000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81512000	USD
CY2013Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	55432000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19087000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1475000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	786000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	91869000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	101385000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	481000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	458000	USD
CY2013Q1	us-gaap	Assets Assets	93700000	USD
CY2012Q4	us-gaap	Assets Assets	103017000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5719000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5661000	USD
CY2013Q1	snta	Accrued Contract Research Costs AccruedContractResearchCosts	4901000	USD
CY2012Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	4761000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	11000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000	USD
CY2013Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	3081000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7924000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16551000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23486000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1000	USD
CY2013Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	20545000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4464000	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	20545000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4465000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	37096000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	27951000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93700000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103017000	USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69129951	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69129951	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68930082	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68930082	shares
CY2012Q1	snta	Total Revenues TotalRevenues	147000	USD
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16380000	USD
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12066000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3878000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2646000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	20258000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	14712000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20258000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14565000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-470000	USD
CY2012Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-486000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20728000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15051000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68991371	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56366992	shares
CY2013Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20723000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15035000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	16000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1216000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	827000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	689000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	23000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-112000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	58000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-427000	USD
CY2013Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	140000	USD
CY2012Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	1166000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2288000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2064000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22214000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12280000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	33050000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-46550000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15254000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	55290000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	22824000	USD
CY2013Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	18950000	USD
CY2012Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9650000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	276000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-36616000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13321000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1045000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28204000	USD
CY2012Q1	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	5000000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	13210000	USD
CY2013Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1972000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4475000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	789000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	485000	USD
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1) Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> </div>
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69133471	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34550000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	11000	USD

Files In Submission

Name	View Source	Status
0001104659-13-034655-index-headers.html	Edgar Link	pending
0001104659-13-034655-index.html	Edgar Link	pending
0001104659-13-034655.txt	Edgar Link	pending
0001104659-13-034655-xbrl.zip	Edgar Link	pending
a13-8536_110q.htm	Edgar Link	pending
a13-8536_1ex10d2.htm	Edgar Link	pending
a13-8536_1ex10d3.htm	Edgar Link	pending
a13-8536_1ex31d1.htm	Edgar Link	pending
a13-8536_1ex31d2.htm	Edgar Link	pending
a13-8536_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20130331.xml	Edgar Link	completed
snta-20130331.xsd	Edgar Link	pending
snta-20130331_cal.xml	Edgar Link	unprocessable
snta-20130331_def.xml	Edgar Link	unprocessable
snta-20130331_lab.xml	Edgar Link	unprocessable
snta-20130331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2013 Q2 Form 10-Q Financial Statement

#000110465913034655 Filed on April 30, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2013 Q2 Form 10-Q Financial Statement

#000110465913034655 Filed on April 30, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl